Corgenix
This article was originally published in The Gray Sheet
Executive Summary
Worldwide distribution of firm's diagnostic tests to detect hyaluronic acid in patients with rheumatoid arthritis will commence pending FDA clearance of July 9 510(k) submission, Corgenix says. Test will be used as an aid in the serological evaluation of rheumatic disease with synovial inflammation